207 related articles for article (PubMed ID: 24611802)
1. Design of intrahepatocyte copper(I) chelators as drug candidates for Wilson's disease.
Gateau C; Delangle P
Ann N Y Acad Sci; 2014 May; 1315():30-6. PubMed ID: 24611802
[TBL] [Abstract][Full Text] [Related]
2. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
Delangle P; Mintz E
Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
[TBL] [Abstract][Full Text] [Related]
3. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
4. Clinical considerations for an effective medical therapy in Wilson's disease.
Weiss KH; Stremmel W
Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
[TBL] [Abstract][Full Text] [Related]
5. Chelating polymeric beads as potential therapeutics for Wilson's disease.
Mattová J; Poučková P; Kučka J; Skodová M; Vetrík M; Stěpánek P; Urbánek P; Petřík M; Nový Z; Hrubý M
Eur J Pharm Sci; 2014 Oct; 62():1-7. PubMed ID: 24815561
[TBL] [Abstract][Full Text] [Related]
6. A sulfur tripod glycoconjugate that releases a high-affinity copper chelator in hepatocytes.
Pujol AM; Cuillel M; Jullien AS; Lebrun C; Cassio D; Mintz E; Gateau C; Delangle P
Angew Chem Int Ed Engl; 2012 Jul; 51(30):7445-8. PubMed ID: 22730309
[No Abstract] [Full Text] [Related]
7. Hepatic copper and metallothionein distribution in Wilson's disease (hepatolenticular degeneration).
Nartey NO; Frei JV; Cherian MG
Lab Invest; 1987 Oct; 57(4):397-401. PubMed ID: 3312808
[TBL] [Abstract][Full Text] [Related]
8. [Copper level and metallothionein-like Cu-binding protein in cultured skin fibroblasts from patients with Menkes' disease and Wilson's disease].
Sato M; Hayashi A; Ito H; Tojo M; Arima M
No To Shinkei; 1984 Nov; 36(11):1063-8. PubMed ID: 6525319
[TBL] [Abstract][Full Text] [Related]
9. Activation of HIF-1 signaling ameliorates liver steatosis in zebrafish atp7b deficiency (Wilson's disease) models.
Mi X; Li Z; Yan J; Li Y; Zheng J; Zhuang Z; Yang W; Gong L; Shi J
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165842. PubMed ID: 32446740
[TBL] [Abstract][Full Text] [Related]
10. Wilson's disease.
Loudianos G; Gitlin JD
Semin Liver Dis; 2000; 20(3):353-64. PubMed ID: 11076401
[TBL] [Abstract][Full Text] [Related]
11. Wilson's disease: a new gene and an animal model for an old disease.
Cuthbert JA
J Investig Med; 1995 Aug; 43(4):323-36. PubMed ID: 7552582
[TBL] [Abstract][Full Text] [Related]
12. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
13. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
14. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
Hoogenraad TU
Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
[TBL] [Abstract][Full Text] [Related]
15. The link between copper and Wilson's disease.
Purchase R
Sci Prog; 2013; 96(Pt 3):213-23. PubMed ID: 24244969
[TBL] [Abstract][Full Text] [Related]
16. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
17. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.
Smirnova J; Kabin E; Järving I; Bragina O; Tõugu V; Plitz T; Palumaa P
Sci Rep; 2018 Jan; 8(1):1463. PubMed ID: 29362485
[TBL] [Abstract][Full Text] [Related]
18. [Current principles of Wilson's disease--diagnosis and treatment].
Najda J; Stella-Hołowiecka B; Machalski M; Woszczyk D; Mykała-Cieśla J
Wiad Lek; 2002; 55(9-10):600-7. PubMed ID: 12607416
[TBL] [Abstract][Full Text] [Related]
19. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease.
Krishnan N; Felice C; Rivera K; Pappin DJ; Tonks NK
Genes Dev; 2018 Jul; 32(13-14):944-952. PubMed ID: 29945887
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy to remove excess copper in Wilson's disease.
Gupta S
Ann N Y Acad Sci; 2014 May; 1315(1):70-80. PubMed ID: 24820353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
